Evidence map›Paper›PMID 35221674›Full record

ArticleDrug design, development and therapy2022

Network Pharmacology and Molecular Docking Study of the Chinese Miao Medicine Sidaxue in the Treatment of Rheumatoid Arthritis.

Ning Wu, Taohua Yuan, ZhiXin Yin, Xiaotian Yuan, Jianfei Sun, Zunqiu Wu, Qilong Zhang, Carl Redshaw, Shenggang Yang, Xiaotian Dai

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Psoriasis intervention by Huai'er (): unveiling novel targetsnetwork pharmacology.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Foods (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Ning Wu *Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Taohua Yuan *Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0003-1942-0235
ZhiXin YinGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Xiaotian YuanGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Jianfei SunGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Zunqiu WuGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Qilong ZhangGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Carl RedshawDepartment of Chemistry, University of Hull, Hull, Yorkshire, HU6 7RX, UK.
Shenggang YangGuizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Xiaotian DaiDepartment of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada.ORCID 0000-0003-3203-8110
Guiyang Medical University · CNUniversity of Calgary · CAUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate the molecular mechanisms of Compound Sidaxue (SX), a prescription of Chinese Miao medicine, in treating rheumatoid arthritis (RA) using network pharmacology and in vivo experimental approaches.

methodsNetwork pharmacology was adopted to detect the active components of four Traditional Chinese herbal medicine (TCM) of SX, and the key targets and signaling pathways in the treatment of RA were predicted, and the key components and targets were screened for molecular docking. The predicted targets and pathways were validated in bovine type II collagen and incomplete Freund's adjuvant emulsifier-induced rat RA model.

resultsIn this study, we identified 33 active components from SX, predicted to act on 44 RA-associated targets by network pharmacology. PPI network demonstrated that TNF-α, VEGF-A, IL-2, IL-6, AKT, PI3K, STAT1 may serve as the key targets of SX for the treatment of RA. The main functional pathways involving these key targets include PI3K-AKT signaling pathway, TNF signaling pathway, NF-κB signaling pathway. Molecular docking analysis found that the active components β-amyrin, cajanin, eleutheroside A have high affinity for TNF-α, VEGFA, IL-2, AKT, and PI3K, etc. SX can improve joint swelling in Collagen-induced arthritis (CIA) rats, reduce inflammatory cell infiltration and angiogenesis in joint synovial tissue, and down-regulate IL-2, IL-6, TNF-α, VEGF, PI3K, AKT, p-AKT, NF-κBp65, the expression of p-NF-κBp65, STAT1, and PTGS2 are used to control the exacerbation of inflammation and alleviate the proliferation of synovial pannus, and at the same time play the role of cartilage protection to achieve the effect of treating RA.

conclusionThrough a network pharmacology approach and animal study, we predicted and validated the active compounds of SX and their potential targets for RA treatment. The results suggest that SX can markedly alleviate CIA rat by modulating the VEGF/PI3K/AKT signaling pathway, TNF-α signaling pathway, IL/NF-κB signaling pathway.

Indexed as

Arthritis, RheumatoidDrugs, Chinese HerbalAnimalsCattleChinaMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesRatsDrugs, Chinese HerbalPhosphatidylinositol 3-KinasesIL/NF-κB signaling pathwaymolecular dockingnetwork pharmacologyrheumatoid arthritisSidaxueTNF-α signaling pathwayVEGF/PI3K/AKT signaling pathway

Identifiers

PMID35221674
PMCPMC8865873
OpenAlexW4212951396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.